(Nasdaq: XERS) to return the commercial rights to Ogluo®, a glucagon auto-injector pen for severe hypoglycemia. The decision follows a strategic review which highlighted the financial ...
The global auto-injectors market is on a significant growth trajectory, with market share expected to reach a robust valuation of USD 30,578.2 million in 2023. This figure represents a strong presence ...
The move comes alongside a mutual decision with Xeris BioPharma Holdings, Inc. (Nasdaq: XERS) to return the commercial rights to Ogluo®, a glucagon auto-injector pen for severe hypoglycemia. The ...
adding that it had mutually agreed with Xeris BioPharma to return the rights to Ogluo - a ready-to-use glucagon auto-injector for severe hypoglycemia. The AIM-traded firm said the decision ...